MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • All Meetings
    • 2026 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Ataxia: Treatment"

  • 2022 International Congress

    Geographic and Financial Trends in the Utilization of Deep Brain Stimulation in the Medicare Population from 2013-2019

    T. Gossard, A. Khurana, J. Chan, S. Aslam (Phoenix, USA)

    Objective: To evaluate the utilization of deep brain stimulation within the Medicare population across different regions and states in the United States Background: Deep brain…
  • 2022 International Congress

    Cerebellar transcranial direct current stimulation in spinocerebellar ataxia type 3: a randomized, double-blind, sham-controlled trial

    R. Maas, S. Teerenstra, I. Toni, T. Klockgether, D. Schutter, B. Vande Warrenburg (Nijmegen, Netherlands)

    Objective: To investigate if a 2-week regimen comprising daily sessions of cerebellar anodal transcranial direct current stimulation (tDCS) 1) diminishes ataxia and non-motor symptom severity…
  • 2022 International Congress

    Therapies, Research Funding and Racial Diversity in Cerebellar Ataxia: A Systematic Review of the Literature

    C. Kingsbury, S. Ghanekar, Y. Huang, T. Ashizawa, S. Kuo, C. Gooch, T. Zesiewicz (Tampa, USA)

    Objective: To understand the scope of clinical research in cerebellar ataxia by performing a systematic review of controlled clinical trials over the past 50 years,…
  • 2022 International Congress

    Isolated ZIC4 antibody associated paraneoplastic cerebellar degeneration

    A. Agarwal, A. Garg, A. Srivastava (New Delhi, India)

    Objective: Anti-ZIC4 antibodies have recently been associated with paraneoplastic cerebellar degeneration (PCD) and are usually associated with small cell carcinoma lung. However, most of the…
  • 2022 International Congress

    Gene Expression Quantification to Assess Frataxin Replacement Therapies in Friedreich’s Ataxia

    M. Baile, D. Schecter, A. Miller, T. Galas, N. Scherer, R. Chen, N. Ruiz, D. Bettoun (Philadelphia, USA)

    Objective: To identify genetic disease and efficacy markers for Friedreich’s ataxia (FRDA) Background: FRDA is a genetic disease caused by decreased expression of the mitochondrial…
  • 2022 International Congress

    Leading Therapeutic Molecules Target Transcription Factors Binding to Repressor Region in FXN Gene

    V. Swarup, H. Singh, D. Gupta, I. Singh, A. Srivastava (New Delhi, India)

    Objective: To investigate interactions of transcription factors (TFs) binding to repressor region located upstream to FXN gene with leading therapeutic molecules. Background: Low levels of…
  • MDS Virtual Congress 2021

    Cerebellar bioenergetic depletion following ubiquinol supplementation in a patient with COQ8A-related ataxia

    J. Prasuhn, M. Göttlich, B. Ebeling, C. Bodemann, S. Großer, I. Wellach, K. Reuther, H. Hanssen, N. Brüggemann (Lübeck, Germany)

    Objective: To non-invasively map the individual treatment response in a patient with COQ8A-related ataxia following coenzyme Q10 supplementation. Background: Primary coenzyme Q10 (CoQ10) deficiency is…
  • MDS Virtual Congress 2020

    Effects of deep transcranial magnetic stimulation of the cerebellum on cerebellar ataxias: A randomized, double-blind, cross-over clinical trial

    C. França, D. de Andrade, V. Silva, R. Galhardoni, E. Barbosa, M. Teixeira, R. Cury (Sao Paulo, Brazil)

    Objective: To investigate whether cerebellar deep repetitive transcranial magnetic stimulation (d-rTMS) can improve ataxic symptoms when compared to sham stimulation. Background: Cerebellar ataxia remains a…
  • MDS Virtual Congress 2020

    A randomized, sham-controlled, crossover trial on Cerebello-Spinal Transcranial pulsed current stimulation (tPCS) in Ataxia

    J. Ganguly, D. Kulshreshtha, S. Soltani, Y. Krishnasamy Tamilselvam, O. Samotus, D. Aur, M. Jog (London, ON, Canada)

    Objective: Patients of degenerative cerebellar ataxia present with slurring of speech, imbalance during walking and problem of co-ordination in limbs.  Currently no effective treatment is…
  • MDS Virtual Congress 2020

    Plasma biomarker quantification in SCA3 using the Neurology 4-PLEX A kit and the Simoa technology

    H. Garcia-Moreno, G. Thomas-Black, A. Heslegrave, H. Zetterberg, P. Giunti (London, United Kingdom)

    Objective: We present the results of plasma biomarker quantification in a cohort of spinocerebellar ataxia type-3 (SCA3) carriers using a Simoa assay. Background: Development of…
  • « Previous Page
  • 1
  • …
  • 4
  • 5
  • 6
  • 7
  • 8
  • …
  • 10
  • Next Page »

Related Sites

International Parkinson and Movement Disorder Society

The Society that manages the annual International Congress »

International Congress

The official website for the International Congress of Parkinson’s and Movement Disorders® »

  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley